Table 2. Number (%) of patients corresponding to each of the six progression pathways by stage.
| Stage | Progression pathway | Total | |||||
|---|---|---|---|---|---|---|---|
| PW1 | PW2 | PW3 | PW4 | PW5 | PW6 | ||
| IA | 17 (3.6) | 7 (1.5) | 16 (3.4) | 17 (3.6) | 381 (81.6) | 29 (6.2) | 467 |
| IB | 9 (3.9) | 4 (1.7) | 11 (4.8) | 20 (8.7) | 167 (72.3) | 20 (8.7) | 231 |
| IIA | 3 (4.6) | 7 (10.8) | 4 (6.2) | 8 (12.3) | 37 (56.9) | 6 (9.2) | 65 |
| IIB | 10 (5.4) | 12 (6.5) | 18 (9.7) | 31 (16.7) | 90 (48.4) | 25 (13.4) | 186 |
| Total | 39 (4.1) | 30 (3.2) | 49 (5.2) | 76 (8.0) | 675 (71.1) | 80 (8.4) | 949 |
PW1: alive or censored with locoregional recurrence; PW2: dead with locoregional recurrence; PW3: alive or censored with distant metastasis; PW4: dead with distant metastasis; PW5: alive or censored without recurrence; PW6: dead without recurrence.